Metastatic Esophageal Cancer Clinical Trial
The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to advanced esophageal cancer.
By enrolling patients with pancreatic cancer adapted to enrolled criteria, this study will
document for the first time the safety and the short and long term efficacy of the combined
therapy using cryosurgery and nature killer (NK) cells for advanced esophageal cancer.
The safety will be evaluated by statistics of adverse reactions.The efficacy will be
evaluated according to local relief degree, progress free survival (PFS) and overall survival
(OS).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02544737 -
Apatinib for Metastatic Esophageal Cancer.
|
Phase 2 | |
| Recruiting |
NCT02545751 -
SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer
|
Phase 2 | |
| Recruiting |
NCT04166721 -
WaKING: Wnt and checKpoint INhibition in Gastric Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06251973 -
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
|
Phase 2 | |
| Completed |
NCT01715233 -
Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer.
|
Phase 2 | |
| Not yet recruiting |
NCT06250036 -
Peri-operative Zimberelimab (Anti-PD-1) vs Zimberelimab in Combination With Domvanalimab (Anti-TIGIT) in Resectable Mismatch Repair Deficient/Micro-satellite Unstable Gastric and Gastro-oesophageal Junctional Adenocarcinoma (ZODIAC)
|
Phase 2 |